PT108.S2.Q19 > Question

SECTION 1 · rc

PASSAGE 1

Question 1 Question 2 Question 3 Question 4 Question 5 Question 6 Question 7 Question 8

PASSAGE 2

Question 9 Question 10 Question 11 Question 12 Question 13 Question 14 Question 15 Question 16

PASSAGE 3

Question 17 Question 18 Question 19 Question 20 Question 21

PASSAGE 4

Question 22 Question 23 Question 24 Question 25 Question 26

SECTION 2 · lr

Question 1 Question 2 Question 3 Question 4 Question 5 Question 6 Question 7 Question 8 Question 9 Question 10 Question 11 Question 12 Question 13 Question 14 Question 15 Question 16 Question 17 Question 18 Question 19 Question 20 Question 21 Question 22 Question 23 Question 24

SECTION 3 · lr

SECTION 4 · rc

PASSAGE 1

Question 1 Question 2 Question 3 Question 4 Question 5 Question 6 Question 7

PASSAGE 2

Question 8 Question 9 Question 10 Question 11 Question 12 Question 13 Question 14 Question 15

PASSAGE 3

Question 16 Question 17 Question 18 Question 19 Question 20

PASSAGE 4

Question 21 Question 22 Question 23 Question 24 Question 25 Question 26 Question 27

The editorial argues that copycat “me too” drugs can benefit consumers. Why? Because their presence sometimes reduces the prices of the drugs they resemble.

The editorial assumes consumers can benefit from the price reduction caused by “me too” drugs entering the market. This means assuming the lower prices are enjoyed by end consumers and that they aren’t accompanied by some disadvantage that outweighs the benefit of lower prices.

This is another way “me too” drugs can benefit consumers. It rules out the possibility that all “me too” drugs are less effective than the originals.

This weakens the editorial’s argument because it suggests consumers might benefit in a different way if “me too” drugs were prohibited: from the availability of more innovative drugs.

This doesn’t prevent “me too” drugs from benefitting consumers as well. Pharmaceutical companies might make more money on “me too” drugs simply because the lower price allows more people to purchase them.

The editorial says “[m]any” pharmaceutical companies, not all of them, produce “me too” drugs. Even if fewer innovative drugs were developed, that would disadvantage consumers, so this would weaken the argument.

This disadvantages some pharmaceutical companies, but it doesn’t necessarily benefit consumers. It’s not stated whether losses by the companies that develop innovative drugs translate to savings by consumers.

PrepTest 108 - Section 2 - Question 19

Difficulty

Analysis

Answer Popularity

Question history

Confirm action